ITGA4 and autoimmune disease: Although we have not yet identified a similar polymorphism in human α4, we can envisage a scenario in which particular ITGA4 polymorphisms in humans might negatively impact the efficacy of natalizumab for treating neurological disorders as well as other autoimmune diseases.